iOnctura SA, a clinical stage precision oncology company, has appointed Steven Sciuto as chief financial officer and Michelle Tsai as chief operating officer to strengthen its executive team amid progress in trials of its lead asset roginolisib. Roginolisib is being investigated in multiple randomised Phase 2 studies in solid and haematological malignancies. The new CFO brings 15 years of corporate finance leadership and capital markets experience in the life sciences industry. Mr Sciuto was most recently vice president finance at Neurogene. The new COO brings two decades of experience in oncology and specialty pharmaceuticals, and has held senior positions at global pharmaceutical companies, including leading commercial launches in oncology for Novartis.
Copyright 2025 Evernow Publishing Ltd